USA: Cambrex Announces Investment Expansion of Large Scale, Multi-Purpose Manufacturing Capabilities

Editor: Alexander Stark

Cambrex, manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), announced a SEK 72 million ($ 9 million) investment to expand large scale manufacturing capacity at its Karlskoga facility in Sweden.

Related Companies

The expansion at Cambrex’s Swedish site is part of an ongoing strategic campaign to invest in small molecule API manufacturing.
The expansion at Cambrex’s Swedish site is part of an ongoing strategic campaign to invest in small molecule API manufacturing.
(Source: Cambrex)

East Rutherford/USA — The investment includes the installation of new multi-purpose reactors ranging from 4 to 12m 3 and upgrading of the control room within an existing plant on site. The new facilities will undergo validation and cGMP qualification ahead of the operational startup in Q4 2016. This extra capacity increases the large scale manufacturing capabilities of the Karlskoga facility, which supports clients’ development projects from R&D through to large scale commercial manufacturing. “Our facility at Karlskoga is strategically important, both in Scandinavia and the wider European markets, and this investment is in response to an increase in demand for larger scale, multi-purpose manufacturing capabilities,” commented Bjarne Sandberg, Managing Director, Cambrex Karlskoga.

(ID:44256616)